CHERYL-LISA BENNETT: Open Payments
NPI 1649394461 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,879 in 46 payments from 9 companies in 2025. Trend: 2023 $1,296 · 2024 $747 · 2025 $1,879
Food & beverage: $1,879
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 9 | $493 |
| E.R. Squibb & Sons, L.L.C. | 12 | $456 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $352 |
| Otsuka America Pharmaceutical, Inc. | 8 | $269 |
| Teva Pharmaceuticals USA, Inc. | 5 | $140 |
| Lundbeck LLC | 3 | $79 |
| Alkermes, Inc. | 2 | $50 |
| Luye Pharma (USA) Ltd. | 1 | $22 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
Products named: INVEGA SUSTENNA, COBENFY, CAPLYTA, REXULTI, AUSTEDO XR, ABILIFY MAINTENA, ARISTADA, ERZOFRI EXTENDED-RELEASE.
Industry payments across NY — which companies pay providers there.
